尼克洛萨米德强化TMEM16A,并诱导血管收缩
Pengfei Liang1, Yui Chun S Wan1, Kuai Yu2
1Department of Biochemistry, Duke University School of Medicine, NC 27710, USA.
尼克洛萨米德意外地增强了,而不是抑制了TMEM16A通道,这与之前的假设相反. 这一发现提醒人们不要使用尼克洛萨米德治疗喘或高血压等疾病.
科学领域:
- 离子通道药理学 离子通道药理学
- 疾病的分子机制.
背景情况:
- 激活化通道TMEM16A是治疗喘和COPD等疾病的关键目标.
- 尼克洛萨米德是一种杀虫剂,作为TMEM16A抑制剂进行了研究,但已知有脱效应.
结论:
- 尼克洛萨米德对TMEM16A的增强需要在喘,COPD和高血压治疗中谨慎使用.
- 鉴定的结合部位为开发特定的TMEM16A调节器提供了洞察力.
- 需要进一步的研究来了解精确的机制和治疗影响.
更多相关视频
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
06:40Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
Published on: April 23, 2020
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Heart Failure Drugs: Inotropic Agents
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
